{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T21:50:58Z","timestamp":1773006658740,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s11523-024-01094-5","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T04:01:51Z","timestamp":1726804911000},"page":"925-939","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01"],"prefix":"10.1007","volume":"19","clinical-trial-number":[{"clinical-trial-number":"umin000050552","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1638-5027","authenticated-orcid":false,"given":"Makoto","family":"Hibino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5202-531X","authenticated-orcid":false,"given":"Yoshinori","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8601-0442","authenticated-orcid":false,"given":"Rai","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4814-4401","authenticated-orcid":false,"given":"Tomoya","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8483-7788","authenticated-orcid":false,"given":"Ryuta","family":"Fukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-844X","authenticated-orcid":false,"given":"Yusuke","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6068-1385","authenticated-orcid":false,"given":"Kiyoaki","family":"Uryu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1432-6938","authenticated-orcid":false,"given":"Tadahisa","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8902-0056","authenticated-orcid":false,"given":"Masataka","family":"Taguri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8630-9145","authenticated-orcid":false,"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"1094_CR1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","volume":"9","author":"Y Shi","year":"2014","unstructured":"Shi Y, Au JS-K, Thongprasert S, Srinivasan S, Tsai C-M, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014;9:154\u201362. https:\/\/doi.org\/10.1097\/JTO.0000000000000033.","journal-title":"J Thorac Oncol"},{"key":"1094_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et al. Non-small cell lung cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:249\u201374. https:\/\/doi.org\/10.6004\/jnccn.2204.0023.","journal-title":"J Natl Compr Canc Netw"},{"key":"1094_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10147-019-01431-z","volume":"24","author":"H Akamatsu","year":"2019","unstructured":"Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, et al. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol. 2019;24:731\u201370. https:\/\/doi.org\/10.1007\/s10147-019-01431-z.","journal-title":"Int J Clin Oncol"},{"key":"1094_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, FLAURA Investigators, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"key":"1094_CR5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/jjco\/hyad162","volume":"54","author":"K Uryu","year":"2024","unstructured":"Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, et al. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01). Jpn J Clin Oncol. 2024;54:319\u201328. https:\/\/doi.org\/10.1093\/jjco\/hyad162.","journal-title":"Jpn J Clin Oncol"},{"key":"1094_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, FLAURA Investigators, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med"},{"key":"1094_CR7","unstructured":"Nogami N, Ramalingam SS, Imamura F, Okamoto I, Kurata T, Kato T, et al. Osimertinib as first-line therapy for EGFRm advanced NSCLC (FLAURA): final OS in Japanese subset. 60th Annual Meeting of the Japan Lung Cancer Society, Presidential Symposium; 6-8 December, 2019; Osaka."},{"key":"1094_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/jjco\/hyac012","volume":"52","author":"Y Tsukita","year":"2022","unstructured":"Tsukita Y, Inoue A. First-line therapy in non-small cell lung cancer patients with EGFR activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study. Jpn J Clin Oncol. 2022;52:405\u201310. https:\/\/doi.org\/10.1093\/jjco\/hyac012.","journal-title":"Jpn J Clin Oncol"},{"key":"1094_CR9","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.3390\/healthcare10112146","volume":"10","author":"R Shimoyama","year":"2022","unstructured":"Shimoyama R, Imamura Y, Uryu K, Mase T, Fujimura Y, Hayashi M, et al. Real-world outcomes of systemic therapy in Japanese patients with cancer (Tokushukai REAl-World Data project: TREAD): study protocol for a nationwide cohort study. Healthcare (Basel). 2022;10:2146. https:\/\/doi.org\/10.3390\/healthcare10112146.","journal-title":"Healthcare (Basel)."},{"issue":"4","key":"1094_CR10","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"1094_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12(10): e1001885. https:\/\/doi.org\/10.1371\/journal.pmed.1001885.","journal-title":"PLoS Med"},{"key":"1094_CR12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","volume":"2","author":"P Goldstraw","year":"2007","unstructured":"Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, International Association for the Study of Lung Cancer International Staging Committee, Participating Institutions, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706\u201314. https:\/\/doi.org\/10.1097\/JTO.0b013e31812f3c1a.","journal-title":"J Thorac Oncol"},{"key":"1094_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","volume":"151","author":"FC Detterbeck","year":"2017","unstructured":"Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151:193\u2013203. https:\/\/doi.org\/10.1016\/j.chest.2016.10.010.","journal-title":"Chest"},{"key":"1094_CR14","unstructured":"Japan Pharmaceuticals and Medical Devices Agency (PMDA). Tagrisso: package insert. https:\/\/www.info.pmda.go.jp\/go\/pack\/4291045F1027_1_12\/. Accessed 14 Mar 2024."},{"key":"1094_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, AURA3 Investigators, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1612674.","journal-title":"N Engl J Med"},{"key":"1094_CR16","doi-asserted-by":"publisher","first-page":"e21128","DOI":"10.1200\/JCO.2023.41.16_suppl.e211","volume":"41","author":"Y Liu","year":"2023","unstructured":"Liu Y, Bi J, Moreira A, Chachoua A, Velcheti V, Lau SCM, et al. Real-world clinical outcomes in a US Asian population with stage IV NSCLC treated with osimertinib (Osi) stratified by EGFR subtype. J Clin Oncol. 2023;41:e21128. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e211.","journal-title":"J Clin Oncol"},{"key":"1094_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100085","volume":"1","author":"N Haratake","year":"2020","unstructured":"Haratake N, Misumi T, Yamanaka T, Seto T. Optimizing sequential treatment with EGFR tyrosine kinase inhibitor with a simulation of the T790M mutation rate in EGFR-mutated lung cancer. JTO Clin Res Rep. 2020;1: 100085. https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100085.","journal-title":"JTO Clin Res Rep."},{"key":"1094_CR18","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1248\/bpb.b22-00794","volume":"46","author":"T Hori","year":"2023","unstructured":"Hori T, Yamamoto K, Ito T, Ikushima S, Omura T, Yano I. Upfront use of first-\/second-generation EGFR-TKI followed by osimertinib shows better prognosis than upfront osimertinib therapy in Japanese patients with non-small-cell lung cancer with exon 19 deletion: a single-center retrospective study. Biol Pharm Bull. 2023;46:788\u201395. https:\/\/doi.org\/10.1248\/bpb.b22-00794.","journal-title":"Biol Pharm Bull"},{"key":"1094_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jjco\/hyy179","volume":"49","author":"Y Ohe","year":"2019","unstructured":"Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, et al. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J Clin Oncol. 2019;49:29\u201336. https:\/\/doi.org\/10.1093\/jjco\/hyy179.","journal-title":"Jpn J Clin Oncol"},{"key":"1094_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e21159","volume":"41","author":"I Michelon","year":"2023","unstructured":"Michelon I, Vilbert M, Castro C, Stecca C, Dacoregio MI, Rizzo MM, et al. Retreatment with EGFR inhibitor in non-small cell lung cancer patients previously exposed to EGFR-TKI: a systematic review and meta-analysis. J Clin Oncol. 2023;41: e21159. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e21159.","journal-title":"J Clin Oncol"},{"key":"1094_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41571-021-00558-1","volume":"19","author":"A Friedlaender","year":"2022","unstructured":"Friedlaender A, Subbiah V, Russo A, Banna GL, Malapelle U, Rolfo C, et al. EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. Nat Rev Clin Oncol. 2022;19:51\u201369. https:\/\/doi.org\/10.1038\/s41571-021-00558-1.","journal-title":"Nat Rev Clin Oncol"},{"key":"1094_CR22","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","volume":"19","author":"M Borgeaud","year":"2024","unstructured":"Borgeaud M, Parikh K, Banna GL, Kim F, Olivier T, Le X, et al. Unveiling the landscape of uncommon EGFR mutations in NSCLC: a systematic review. J Thorac Oncol. 2024;19:973\u201383. https:\/\/doi.org\/10.1016\/j.jtho.2024.03.016.","journal-title":"J Thorac Oncol"},{"key":"1094_CR23","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","volume":"389","author":"C Zhou","year":"2023","unstructured":"Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, PAPILLON Investigators, et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med. 2023;389:2039\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2306441.","journal-title":"N Engl J Med"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01094-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01094-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01094-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T05:06:45Z","timestamp":1731474405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01094-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1094"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01094-5","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,20]]},"assertion":[{"value":"23 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Makoto Hibino received research funding from and engaged in collaborative research with Shionogi & Co., Ltd. outside the submitted work. Tomoya Fukui received speakers\u2019 bureau fees\/honoraria from AstraZeneca, Boehringer Ingelheim, Chugai Pharm, Eli Lilly, Nippon Kayaku, Novartis Pharma, Ono Pharm, Pfizer, and Taiho Pharm outside the submitted work. Imamura received speakers\u2019 bureau fees\/honoraria from Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Pfizer, and Ono Pharm outside the submitted work. Minami received speakers\u2019 bureau fees\/honoraria from Daiichi-Sankyo and Ono Pharm; research funding from Astelas-Amgen Biopharma, Bayer, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Incite, Novartis, Ono Pharm, Pfizer, and Rakuten Medical; and scholarship donations from Bayer, Chugai, Daiichi-Sankyo, Eisai, Kyowa-Kirin, Lilly, Ono Pharmaceutical, Pfizer, Taiho Pharma, and Takeda outside the submitted work. These organizations had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. Rai Shimoyama, Ryuta Fukai, Akihiko Iwase, Yukihiro Tamura, Yusuke Chihara, Takafumi Okabe, Uryu Kiyoaki, Tadahisa Okuda, and Masataka Taguri have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted following the principles of the Declaration of Helsinki and was reviewed and approved by the Ethics Committee of the Tokushukai Group on 2 March, 2023 (approval number: TGE 01427-008). This study was registered at the University Hospital Medical Information Network Clinical Trials Registry on 9 March, 2023 (identification UMIN000050552).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The requirement for obtaining informed consent from patients was waived because this was a retrospective analysis of anonymized patient data. Patients were allowed to opt out of the research use of their data, and related information is publicly available on the Tokushukai Medical Group website.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data supporting the findings of this study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization, data curation, formal analysis, investigation, methodology, resources, writing (original draft): MH. Resources, writing (review and editing): KU. Resources, writing (review and editing): RS. Resources, writing (review and editing): TF. Resources, writing (review and editing): RF. Resources, writing (review and editing): AI. Resources, writing (review and editing): YT. Resources, writing (review and editing): YC. Resources, writing (review and editing): MF. Formal analysis: TO. Formal analysis: MT. Writing (review and editing): YI. Writing (review and editing): HM.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}